NCT06650007View on ClinicalTrials.gov

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

218

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

May 14, 2025

Study Completion Date

July 31, 2026

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

HRS9531 Injection

DRUG

HRS9531 Placebo Injection

Trial Locations (1)

410100

The Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06650007 - the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone | Biotech Hunter | Biotech Hunter